MedTrace Logo

To Evaluate the Efficacy and Safety of SR419 in Patients With Postherpetic Neuralgia (PHN)

NCT05357677 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2024-01-05

No results posted yet for this study

Summary

This is a Phase II, international multicenter, double-blind, placebo-controlled, crossover study to assess the efficacy of SR419 in PHN subjects.

Conditions

  • Postherpetic Neuralgia

Interventions

DRUG

SR419

SR419 capsule

Sponsors & Collaborators

  • Shanghai SIMR Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Fa Bi Fan, MD · China-Japan Friendship Hospital

  • Yong Cui, MD · China-Japan Friendship Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-13
Primary Completion
2023-01-13
Completion
2023-01-18

Countries

  • Australia
  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05357677 on ClinicalTrials.gov